Welcome to our new website! Let us know what you think..

Register to get unlimited access to all of Citywire’s Fund Manager database. Registration is free and only takes a minute.

Woodford takes 19% stake in biotech minnow

Woodford takes 19% stake in biotech minnow

Neil Woodford, the best UK investor of his generation, has taken a big chunk of biotech minnow Synairgen a month after it licensed an asthma drug for a fee worth up to $225 million (£131 million).

Citywire A-rated Woodford went from below a reportable holding in the business to owning 19% in one purchase, or 17.45 million shares worth £9.07 million at a share price of 52p.

The manager - who has offered the best long-term risk-adjusted return of any UK investor - left Invesco Perpetual, his employer of more than 25 years, earlier this year to launch his own business.

Shares in Synairgen briefly spiked more than 40% in June following the announcement of the deal with AstraZeneca, before deflating as the company placed 12.2 million shares to fund development.

AstraZeneca will pay the company an up-front fee of $7.25 million with the remainder subject to expectations, in addition to royalties. Broker finnCap has a 108p target price on the business.

Leave a comment!

Please sign in or register to comment. It is free to register and only takes a minute or two.

Related Fund Managers

Neil Woodford
Neil Woodford
29/72 in Equity - UK Equity Income (Performance over 3 years) Average Total Return: 58.64%
Your Business: Cover Star Club

Profile: why Chris Wyllie joined Connor Broadley

Profile: why Chris Wyllie joined Connor Broadley

Professional footballers are not renowned for their financial acumen, but former Millwall player James Connor is an exception to the rule

Wealth Manager on Twitter